MA29735B1 - MICROPARTICLE COMPOSITION CONTAINING TOPOISOMERASE 1, 7-TERTBUTOXYIMINOMETHYLCAMPTOTHECIN INHIBITOR - Google Patents

MICROPARTICLE COMPOSITION CONTAINING TOPOISOMERASE 1, 7-TERTBUTOXYIMINOMETHYLCAMPTOTHECIN INHIBITOR

Info

Publication number
MA29735B1
MA29735B1 MA30631A MA30631A MA29735B1 MA 29735 B1 MA29735 B1 MA 29735B1 MA 30631 A MA30631 A MA 30631A MA 30631 A MA30631 A MA 30631A MA 29735 B1 MA29735 B1 MA 29735B1
Authority
MA
Morocco
Prior art keywords
inhibitor
tertbutoxyiminomethylcamptothecin
composition containing
microparticle composition
topoisomerase
Prior art date
Application number
MA30631A
Other languages
French (fr)
Inventor
Isabel Ottinger
Oskar Kalb
Walter Stebler
Agnes Taillardat
Wolfgang Wirth
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37056484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29735(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29735B1 publication Critical patent/MA29735B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

CETTE INVENTION CONCERNE DES COMPOSITIONS PHARMACEUTIQUES DE MICROPARTICULES DANS LESQUELLES LE PRINCIPE ACTIF EST UN INHIBITEUR DE LA TOPOISOMÉRASE 1, PLUS PARTICULIÈREMENT, LA 7-TERT-BUTOXYIMINOMETHYLCAMPTOTHÉCINE, PERMETTANT DE TRAITER ET DE PRÉVENIR DES MALADIES PROLIFÉRANTES PARMI LESQUELLES LE CANCER.THIS INVENTION INVOLVES PHARMACEUTICAL COMPOSITIONS OF MICROPARTICLES IN WHICH THE ACTIVE INGREDIENT IS A TOPOISOMERASE 1 INHIBITOR, PARTICULARLY 7-TERT-BUTOXYIMINOMETHYLCAMPTOTHECIN, FOR THE TREATMENT AND PREVENTION OF PROLIFERATIVE DISEASES AMONG WHICH CANCER.

MA30631A 2005-08-10 2008-02-08 MICROPARTICLE COMPOSITION CONTAINING TOPOISOMERASE 1, 7-TERTBUTOXYIMINOMETHYLCAMPTOTHECIN INHIBITOR MA29735B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70713905P 2005-08-10 2005-08-10

Publications (1)

Publication Number Publication Date
MA29735B1 true MA29735B1 (en) 2008-09-01

Family

ID=37056484

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30631A MA29735B1 (en) 2005-08-10 2008-02-08 MICROPARTICLE COMPOSITION CONTAINING TOPOISOMERASE 1, 7-TERTBUTOXYIMINOMETHYLCAMPTOTHECIN INHIBITOR

Country Status (20)

Country Link
EP (1) EP1915132A1 (en)
JP (1) JP2009504616A (en)
KR (1) KR20080034989A (en)
CN (1) CN101287448A (en)
AR (1) AR055602A1 (en)
AU (1) AU2006277879A1 (en)
BR (1) BRPI0614757A2 (en)
CA (1) CA2618084A1 (en)
EC (1) ECSP088166A (en)
GT (1) GT200600364A (en)
IL (1) IL189076A0 (en)
MA (1) MA29735B1 (en)
MX (1) MX2008001965A (en)
NO (1) NO20081213L (en)
PE (1) PE20070232A1 (en)
RU (1) RU2008108885A (en)
TN (1) TNSN08062A1 (en)
TW (1) TW200800195A (en)
WO (1) WO2007017514A1 (en)
ZA (1) ZA200800726B (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
IT1306129B1 (en) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti ESTERS OF L-CARNITINE OR ALCANOYL L-CARNITINE USABLE CATIONIC COMELIPIDS FOR INTRACELLULAR PLACING OF COMPOUNDS
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
GT200500310A (en) * 2004-11-19 2006-06-19 ORGANIC COMPOUNDS

Also Published As

Publication number Publication date
TW200800195A (en) 2008-01-01
CN101287448A (en) 2008-10-15
ECSP088166A (en) 2008-03-26
AR055602A1 (en) 2007-08-29
MX2008001965A (en) 2008-03-26
RU2008108885A (en) 2009-09-20
AU2006277879A1 (en) 2007-02-15
TNSN08062A1 (en) 2009-07-14
ZA200800726B (en) 2009-08-26
PE20070232A1 (en) 2007-04-09
GT200600364A (en) 2007-03-19
KR20080034989A (en) 2008-04-22
CA2618084A1 (en) 2007-02-15
WO2007017514A1 (en) 2007-02-15
IL189076A0 (en) 2008-08-07
EP1915132A1 (en) 2008-04-30
BRPI0614757A2 (en) 2011-04-12
JP2009504616A (en) 2009-02-05
NO20081213L (en) 2008-05-13

Similar Documents

Publication Publication Date Title
EA200600414A1 (en) BORONIC ACID DERIVATIVES (OPTIONS), INTERMEDIATE CONNECTIONS, METHODS OF OBTAINING THEM, COMPOSITION FOR INHIBITING NF-kB ACTIVITY AND PROGRAM DEGRADATION AND METHODS OF DISEASE TREATMENT (OPTIONS)
EA200870019A1 (en) LACTAMIC CONNECTIONS AND METHODS OF THEIR APPLICATION
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
MX2009000285A (en) Substituted piperidines that increase p53 activity and the uses thereof.
MXPA05014166A (en) Methods and compositions for treating amyloid-related diseases.
TW200716546A (en) Oxindole compounds and their uses as therapeutic agents
ECSP045429A (en) COMBINATION OF ORGANIC COMPOUNDS
GT200600028A (en) COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEINA KINASA
ECSP056173A (en) COMPOSITION THAT INCLUDES A PDE4 INHIBITOR AND A PDE5 INHIBITOR
NO20055891L (en) Quinazoline derivatives as aurorakinase inhibitors
WO2005117882A8 (en) Hydroxamic acid derivatives as metalloprotease inhibitors
TNSN07193A1 (en) Pharmaceutical compositions comprising a camptothecin derivate
NO20082292L (en) Antiproliferative combination therapy using certain platinum-based chemotherapeutic agents and EGFR inhibitors or pyrimidine analogues
HUP0302384A2 (en) Compositions of biochemical compounds involved in bioenergy metabolism of cells and method of use
NO20070580L (en) Treatment of cancer.
BRPI0410727A (en) compound, pharmaceutical composition, and use of a compound
MA30982B1 (en) COMBINATION
UY29239A1 (en) NEW DERIVATIVES OF PYRIDOTIENOPIRIMIDINE
UY29240A1 (en) NEW DERIVATIVES OF PYRIDOTIENOPIRIMIDINE
EA200801244A1 (en) SDF-1 APPLICATION FOR THE TREATMENT AND / OR PREVENTION OF NEUROLOGICAL DISEASES
ATE396986T1 (en) PYRIMIDYLPYRROLE DERIVATIVES THAT ACTION AS KINASE INHIBITORS
EA201201550A1 (en) DERIVATIVES OF ALPHA-KETOAMIDES AS CYSTEINPROTEAS INHIBITORS
MXPA05000765A (en) 5-aryltetrazole compounds, compositions thereof, and uses therefor.
MA35038B1 (en) ASSOCIATION OF A PHOSPHATIDYLINOSITOL-3-KINASE INHIBITOR (PI3K) AND A MTOR INHIBITOR
WO2007017513A3 (en) Formulations for 7-(t-butoxy)iminomethyl camptothecin